TABLE 2

Comparison of physiological, biochemical and admission data between survivors and non-survivors in the group of patients deemed unsuitable for invasive mechanical ventilation (IMV)

All patients considered not suitable for IMVNot suitable for IMV survivorsNot suitable for IMV non-survivorsp-value
Subjects, n982771
Age, mean±sd76.1±4.672.4±4.176.3±4.80.053
Male, n (%)58 (59)14 (52)44 (62)0.362
Clinical Frailty Score, median (range)4 (1–6)3.5 (2–5)4 (1–6)0.022
CPAP/HFNO duration days, median (range)4 (1–24)7 (1–24)4 (1–11)0.172
CPAP/HFNO well tolerated, n (%)81 (83)25 (93)56 (79)0.053
Comorbidities, n (%)
 HTN63 (64)18 (67)45 (58)0.593
 Diabetes mellitus29 (30)9 (33)20 (31)0.539
 COPD32 (33)5 (19)27 (38)0.081
 Asthma6 (6)1 (4)5 (6)0.563
 Home NIV/CPAP12 (12)4 (15)8 (11)0.585
 Previous cancer12 (12)2 (7)10 (19)0.397
 IHD32 (33)5 (19)27 (38)0.081
 Smoking history49 (50)11 (41)38 (54)0.258
 Obesity37 (38)13 (48)24 (34)0.033
Laboratory results, mean±sd
 Admission WCC ×109·L−110.5±5.27.4±4.311.5±5.10.036
 Admission lymphocyte  count ×109·L−10.98±0.60.81±0.461.04±0.750.425
 Admission C-reactive  protein mg·L−1160±105191±78150±1130.160
Observations pre-CPAP/HFNO, mean±sd
 Respiratory rate28.5±6.626.3±5.829.2±6.80.052
 Heart rate97.9±21.989.8±17.1100.6±23.00.089
 Oxygen saturations88.6±7.588.4±7.688.6±5.90.899
PaO2/FIO2 ratio75.7±40.175.1±38.875.9±40.90.932
CPAP/ HFNO settings, mean±sd
 Starting CPAP PEEP9.4±1.68.5±2.09.7±1.40.111
 Starting CPAP FIO270.0±19.775.0±13.868.3±21.40.073
 Starting HFNO flow rate  L·min−154.2±9.251.3±9.955.2±9.10.308
 Starting HFNO FIO268.3±14.466.6±16.769.0±13.80.702

CPAP: continuous positive airway pressure; HFNO: high-flow nasal oxygen; HTN: hypertension; NIV: noninvasive ventilation; IHD: ischaemic heart disease; WCC: white cell count; PaO2: arterial oxygen tension; FIO2: inspiratory oxygen fraction; PEEP: positive end-expiratory pressure.